Toth Financial Advisory’s CRISPR Therapeutics CRSP Stock Holding History

Toth Financial Advisory’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.18K	Hold	40	–	–	﹤0.01%	742
2026 Q1	$1.9K	Hold	40	–	–	﹤0.01%	724
2025 Q4	$2.1K	Hold	40	–	–	﹤0.01%	708
2025 Q3	$2.59K	Hold	40	–	–	﹤0.01%	672
2025 Q2	$1.95K	Buy	+40	New	+$1.55K	﹤0.01%	637
2023 Q3	–	Sell	-5	Closed	-$281	–	778
2023 Q2	$281	Sell	5 -50	-91%	-$2.84K	﹤0.01%	754
2023 Q1	$2.49K	Hold	55	–	–	﹤0.01%	626
2022 Q4	$2.24K	Hold	55	–	–	﹤0.01%	581
2022 Q3	$4K	Hold	55	–	–	﹤0.01%	566
2022 Q2	$3K	Hold	55	–	–	﹤0.01%	550
2022 Q1	$3K	Hold	55	–	–	﹤0.01%	586
2021 Q4	$4K	Hold	55	–	–	﹤0.01%	580
2021 Q3	$6K	Hold	55	–	–	﹤0.01%	534
2021 Q2	$9K	Hold	55	–	–	﹤0.01%	465
2021 Q1	$7K	Sell	55 -4	-7%	-$604	﹤0.01%	493
2020 Q4	$9K	Hold	59	–	–	﹤0.01%	416
2020 Q3	$5K	Hold	59	–	–	﹤0.01%	426
2020 Q2	$4K	Buy	59 +19	+48%	+$1.11K	﹤0.01%	417
2020 Q1	$2K	Buy	+40	New	+$2.06K	﹤0.01%	383
2018 Q4	–	Sell	-100	Closed	-$4K	–	414
2018 Q3	$4K	Hold	100	–	–	﹤0.01%	370
2018 Q2	$6K	Hold	100	–	–	﹤0.01%	342
2018 Q1	$5K	Buy	+100	New	+$4.13K	﹤0.01%	357

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GSK plc London $602M AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Toth Financial Advisory's CRSP Position: Q2 2026 in Review

Toth Financial Advisory held its CRISPR Therapeutics (CRSP) position steady in Q2 2026 at 40 shares worth $2.18K. The position accounts for ﹤0.01% of the portfolio, ranked #742.

Toth Financial Advisory first reported a position in CRSP in Q1 2018 and has held it in 22 quarters since. The position peaked at $9K in Q2 2021. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

Toth Financial Advisory held 40 shares of CRISPR Therapeutics worth $2.18K as of Q2 2026.
Toth Financial Advisory left its CRISPR Therapeutics share count unchanged in Q2 2026.
CRISPR Therapeutics made up ﹤0.01% of Toth Financial Advisory's portfolio in Q2 2026, its #742 holding.
Toth Financial Advisory first reported a position in CRISPR Therapeutics in Q1 2018 and has held it in 22 quarters since.
Toth Financial Advisory's CRISPR Therapeutics position peaked at $9K in Q2 2021.
521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Toth Financial Advisory's 13F filing for Q2 2026, filed 14 Jul 2026.